Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the Ameri...
May 13 2020 - 5:01PM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced that vorasidenib and ivosidenib clinical data will
be presented at the American Society of Clinical Oncology (ASCO)
Annual Meeting being held virtually May 29-31, 2020.
The accepted abstracts are listed below and are available online
on the ASCO meeting library website:
https://meetinglibrary.asco.org/. All oral and poster presentations
will be available on demand for registered meeting attendees on the
ASCO conference website beginning on May 29 at 8:00 a.m. ET.
Oral Presentation:
Title: Vorasidenib (VOR; AG-881), an inhibitor
of mutant IDH1 and IDH2, in patients (pts) with
recurrent/progressive glioma: Updated results from the phase I
non-enhancing glioma populationOral Abstract
Session: Central Nervous System
TumorsAbstract: 2504Presenter:
Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer
Center
Poster Presentations:
Title: INDIGO: A global, randomized,
double-blind, phase III study of vorasidenib (VOR; AG-881) vs
placebo in patients (pts) with residual or recurrent grade II
glioma with an isocitrate dehydrogenase 1/2 (IDH1/2)
mutationPoster Session: Central Nervous System
TumorsAbstract: TPS2574Author:
Ingo K. Mellinghoff, M.D., Memorial Sloan Kettering Cancer
Center
Title: IDH1 mutation detection in plasma
circulating tumor DNA (ctDNA) and association with clinical
response in patients with advanced intrahepatic cholangiocarcinoma
(IHC) from the phase III ClarIDHy studyPoster
Session: Gastrointestinal Cancer – Gastroesophageal,
Pancreatic, and Hepatobiliary Abstract:
4576Author: Elia Aguado-Fraile, Ph.D., Agios
Pharmaceuticals
Title: Ivosidenib (IVO) prior to hematopoietic
cell transplant for patients with IDH1-mutant relapsed or
refractory acute myeloid leukemia (R/R AML)Poster
Session: Hematologic Malignancies – Leukemia,
Myelodysplastic Syndromes, and
AllotransplantAbstract:
7521Author: Courtney D. DiNardo, M.D., University
of Texas MD Anderson Cancer Center
About AgiosAgios is focused on discovering and
developing novel investigational medicines to treat malignant
hematology, solid tumors and rare genetic diseases through
scientific leadership in the field of cellular metabolism. In
addition to an active research and discovery pipeline across these
three therapeutic areas, Agios has two approved oncology precision
medicines and multiple first-in-class investigational therapies in
clinical and/or preclinical development. For more information,
please visit the company's website at www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the potential benefits of TIBSOVO® (ivosidenib) and
vorasidenib; Agios’ plans regarding future data presentations; and
the potential benefit of its strategic plans and focus. The words
“anticipate,” “expect,” “intend,” “potential,” “milestone,” “goal,”
“will,” “on track,” “upcoming,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Agios' current expectations and beliefs. For
example, there can be no guarantee that any product candidate Agios
or its collaborators is developing will successfully commence or
complete necessary preclinical and clinical development phases, or
that development of any of Agios' product candidates will
successfully continue. Moreover, there can be no guarantee that the
two approved oncology precision medicines being commercialized by
Agios and its collaborators will receive commercial acceptance.
There can be no guarantee that any positive developments in Agios'
business will result in stock price appreciation. Management's
expectations and, therefore, any forward-looking statements in this
press release could also be affected by risks and uncertainties
relating to a number of other important factors, including, without
limitation: risks and uncertainties related to the impact of the
COVID-19 pandemic to Agios’ business, operations,
strategy, goals and anticipated milestones,
including its ongoing and planned research activities,
ability to conduct ongoing and planned clinical trials, clinical
supply of current or future drug candidates, commercial supply of
current or future approved products, and launching, marketing and
selling current or future approved products; Agios’ results of
clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. FDA, the EMA or other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies; Agios’ ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its
planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios’
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Contacts
Investors:Holly Manning, 617-844-6630Director,
Investor RelationsHolly.Manning@agios.com
Media:Jessica Rennekamp, 857-209-3286Associate
Director, Corporate CommunicationsJessica.Rennekamp@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024